Thermo Fisher Scientific has announced its decision to acquire MTI-GlobalStem. Pursuant to the acquisition, MTI-GlobalStem will be merged into Thermo Fisher’s life sciences solution segment.

"Heptares Therapeutics has announced it will acquire G7 Therapeutics for a purchase consideration of $11.83m."

The acquisition will allow Thermo Fisher to expand its presence in biosciences and develop advanced research products to accelerate drug discovery using cell models.

Heptares Therapeutics has announced it will acquire G7 Therapeutics for a purchase consideration of $11.83m.

Heptares will be renamed as Zurich and G7 Therapeutics will be its wholly owned subsidiary, following the completion of the acquisition.

The acquisition will help Heptares to further expand and strengthen its G protein-coupled receptors platform for structure-based drug designing and development.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Image: Thermo Fisher Scientific has announced its decision to acquire MTI-GlobalStem. Photo: Courtesy of Coolcaesar at en.wikipedia.